Clinical updates, including trial initiations, enrollment status and data readouts and publications: 9 Meters, Achieve, Aileron, Biocardia, Cytodyn, Immutep, Immunovant, Intra-Cellular, Iterum, Kiniksa, KPB, Medicure, Revimmune, TFF, Tonix.

Shares of Kiniksa Pharmaceuticals Ltd. hit a 52-week high on June 29 as pivotal phase III results showed that Arcalyst (rilonacept), a medicine it licensed from Regeneron Pharmaceuticals Inc., led to a 96% reduction in risk of recurrent pericarditis events among 61 people not helped by standard-of-care treatments.

BEIJING – China this week approved both the country’s first mRNA vaccine candidate and its first recombinant protein subunit vaccine to begin clinical trials to fight COVID-19.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Highlight, Janssen, Onconano.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: 9 Meters, Acceleron, Adial, Aiviva, Algernon, Assembly, Astrazeneca, Bergenbio, Geneuro, Insmed, Kiadis, Moberg, Neoimmunetech, Novan, Noxopharm, Oncolytics, Theravance.

While Biohaven Pharmaceutical Holding Co. Ltd.’s phase II/III proof-of-concept study of troriluzole for treating obsessive-compulsive disorder (OCD) failed to meet its primary outcome measure at week 12, the company found enough silver in the study’s lining to press on for a larger phase III trial.

PERTH, Australia – Melbourne-based regenerative medicine company Cynata Therapeutics Ltd. is gearing up to take its Cymerus mesenchymal stem cell (MSC) product candidate, CYP-004, into a phase III trial in osteoarthritis.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aduro, Aerpio, Alexion, Alpine Immune, Biohaven, Grid, Immunomolecular, Karyopharm, Orphazyme, Poxel, Rhythm, Roche, Soligenix, T3D, Windtree, Zealand.